Warning
PAYLESS COMPOUNDERS Recalls Semaglutide-Glycine-Cyanocobalamin Injectable
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0471-2026Drug / Pharmaceutical
PAYLESS COMPOUNDERS Recalls Semaglutide-Glycine-Cyanocobalamin Injectable
PAYLESS COMPOUNDERS, LLC · Class II — Moderate Risk
Product Description
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Reason for Recall
Lack of Assurance of Sterility
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
OR
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
The FDA classified this recall as Class II, indicating the pharmaceutical product may cause temporary health problems or poses a slight threat of a serious nature. PAYLESS COMPOUNDERS, LLC initiated the recall on March 6, 2026 affecting 91 vials. Lack of Assurance of Sterility. The product was distributed in OR. Consumers should check their purchases and discontinue use of any affected product. Contact PAYLESS COMPOUNDERS, LLC for further instructions.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medication Defects.